I agree with most of your points, but I think your
Timeline could be a little ambitious as to cash flow
positive and preclinical trials. Here’s my take for
what it’s worth.
1. I love the recreational market in Vegas. It might
slow future dilution
2. The FDA advisory panel unanimously recommended
approval of GW pharma’s CBD derived drug. In
order to approve the drug, the FDA has to
reschedule Cannabis out of schedule 1 or it can’t be posed.
3. There are bills in the Senate and House that
will force the Justice Department. One part is to
make it very much easier for Universities to due
plant research with fewer barriers. LSU?
4. A few days back there were a few posts
about Growblox-AISCO that were pretty much
ignored. The 10k details the deal that granted rights
The current Puerto Rico operator. GBLX still owns over
60% of the company. The box will grow about 100
pounds on consistent quality and profile product a year.
Not great for the big grower, but ideal
for the researcher who is not dealing in quantity
But wants quality that’s plug and play.
5. There’s an awful lot of money waiting to invest
in the sector but can’t, not the least of which
belongs to Pharma and biotech. I can’t find a lot
of companies that do what GB does. Grow your
own
5. The tissue propagation process they use to
obtain consistency is mostly overlooked, but
could produce significant licensing revenue.
News 
Market Data 
Discover 
